GIST Support International - logo

GIST Support International - R1507
GIST Imagery

R1507

This anti-IGF-1R inhibitor is no longer under development.  Some trials are ongoing but no longer recruiting.

manufacturer website link:  Roche / Genmab

oral or intravenous: Intravenous

Description from NCI Drug Dictionary: A recombinant, fully human monoclonal antibody directed against the insulin-like growth factor-1 receptor (IGF-1R) with potential antineoplastic activity. Anti-IGF-1R human monoclonal antibody R1507 binds to membrane-bound IGF-1R, preventing the binding of the natural ligand IGF-1 and the activation of PI3K/AKT signal transduction; downregulation of the PI3K/AKT survival pathway may result in the induction of apoptosis and decreased cellular proliferation. The activation of IGF-1R, a receptor tyrosine kinase of the insulin receptor superfamily, stimulates cell proliferation, enables oncogenic transformation, and suppresses apoptosis; IGF-1R signaling has been implicated in tumorigenesis and metastasis.

Ongoing Trials:

A Study of R1507 in Patients With Recurrent or Refractory Sarcoma (Phase II, NCT00615680)

A Study of R1507 in Patients With Recurrent or Refractory Sarcoma (NCT00642941)

A Multiple Ascending Dose Study of R1507 in Children and Adolescents With Advanced Solid Tumors
(NCT00560144)

A Multiple Ascending Dose Study of R1507 in Patients With Advanced Solid Tumors.  (NCT00400361)



back to top